Clinical

Dataset Information

0

Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.


ABSTRACT: Interventions: CPT-11 150mg/m2 i.v. (day1) Bev 7.5mg/kg i.v. (day1) S-1 80mg/m2 p.o. (day1-14) to be repeated every 3 weeks Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2621739 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2620502 | ecrin-mdr-crc
| 2619811 | ecrin-mdr-crc
| 2626285 | ecrin-mdr-crc
| 2621742 | ecrin-mdr-crc
| 2625136 | ecrin-mdr-crc
| 2620414 | ecrin-mdr-crc
| 2619370 | ecrin-mdr-crc
| 2621169 | ecrin-mdr-crc
| 2620624 | ecrin-mdr-crc
| 2623313 | ecrin-mdr-crc